Treatment of Cushing’s Disease With Seliciclib | Pacific Neuroscience Institute

Seliciclib (also known as roscovitine) is an investigational medication that is not FDA approved. It is administered orally for 4 days every week for 4 weeks at one of 3 doses/schedules being studied. You will be required to participate in 7 clinic visits, including a screening visit, a baseline visit, weekly visits while on drug treatment, and a final visit at study completion. Routine history and physical with blood, urine tests, ECG, visual field test, and pituitary MRI will be obtained during the visit.

Inclusion Criteria:
• Pituitary ACTH-producing tumor causing Cushing disease, including newly diagnosed Cushing’s disease or recurrent or persistent Cushing’s disease despite standard treatment
• Persistently elevated urinary cortisol levels

This study is being conducted in collaboration with Cedars Sinai Medical Center. Please contact the Pituitary Disorders Center at Pacific Neuroscience Institute for more information | 310-582-7450 | Download PDF flyer